[IMPORTANT NOTICE - INDEPENDENT AGENT AND BROKER COMPENSATION NO COVERAGE IS PROVIDED BY THIS NOTICE. THIS NOTICE DOES NOT AMEND ANY PROVISION OF YOUR POLICY. YOU SHOULD REVIEW YOUR ENTIRE POLICY CAREFULLY FOR COMPLETE INFORMATION ON THE COVERAGES PROVIDED AND TO DETERMINE YOUR RIGHTS AND DUTIES UNDER YOUR POLICY. PLEASE CONTACT YOUR AGENT OR BROKER IF YOU HAVE ANY QUESTIONS]
[FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): December 20, 2011 NF ENERGY SAVING CORPORATION Delaware 000-50155 02-0563302 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) Room 3105, Block C, 390 Qingnian Avenue Heping District Shenyang, P.R. China 11000221 (Zip Code) (8624) 2560-9750 (Former Name or Former Address, if Changed Since Last Report) see]
[FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): December 20, 2011 NF ENERGY SAVING CORPORATION Delaware 000-50155 02-0563302 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) Room 3105, Block C, 390 Qingnian Avenue Heping District Shenyang, P.R. China 11000221 (Zip Code) (8624) 2560-9750 (Former Name or Former Address, if Changed Since Last Report) see]
[Jiayuan Announces Share Repurchase Program BEIJING, December 22, 2011--- Jiayuan.com International Ltd. (Jiayuan or the Company) (NASDAQ: DATE), operator of the largest online dating platform in China, today announced that its board of directors has approved a US$10 million share repurchase program. We are confident in the future of Jiayuans business as we continue to benefit from our clear leadership]
[Jiayuan Announces Share Repurchase Program BEIJING, December 22, 2011--- Jiayuan.com International Ltd. (Jiayuan or the Company) (NASDAQ: DATE), operator of the largest online dating platform in China, today announced that its board of directors has approved a US$10 million share repurchase program. We are confident in the future of Jiayuans business as we continue to benefit from our clear leadership]
[Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to your incorporation of our audit report dated December 23, 2011 relating to the audited financial statements of Shaanxi Weinan Aoxing Pharmaceuticals, LLC as of and for the year ended December 31, 2010 in Form 8-K/A of Biostar Pharmaceuticals, Inc. Certified] [Shaanxi Weinan Aoxing Pharmaceuticals, LLC (formerly Shaanxi Weinan Huaren Pharmaceuticals, Ltd.) Index to Financial Statements Year ended December 31, 2010 Page F-1 Balance Sheet F-2 Statement of Operations F-3 Statement of Stockholders’ Equity F-4 Statement of Cash Flows F-5 Notes to Financial Statements F-6 to F-16 To the Board of Directors Shaanxi Weinan Aoxing Pharmaceuticals, LLC (formerly Shaanxi Weinan Huaren] [UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On October 11, 2011, Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or the “Company”), through its wholly owned variable interest entity, Shaanxi Aoxing Pharmaceutical Co., Ltd., acquired 100% equity interest (the “Acquisition”) of Shaanxi Weinan Aoxing Pharmaceutical, LLC (formerly Shaanxi Weinan Huaren Pharmaceutical, Ltd.) (“Shaanxi Weinan”) at a cash purchase consideration of RMB61]
[Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to your incorporation of our audit report dated December 23, 2011 relating to the audited financial statements of Shaanxi Weinan Aoxing Pharmaceuticals, LLC as of and for the year ended December 31, 2010 in Form 8-K/A of Biostar Pharmaceuticals, Inc. Certified] [Shaanxi Weinan Aoxing Pharmaceuticals, LLC (formerly Shaanxi Weinan Huaren Pharmaceuticals, Ltd.) Index to Financial Statements Year ended December 31, 2010 Page F-1 Balance Sheet F-2 Statement of Operations F-3 Statement of Stockholders’ Equity F-4 Statement of Cash Flows F-5 Notes to Financial Statements F-6 to F-16 To the Board of Directors Shaanxi Weinan Aoxing Pharmaceuticals, LLC (formerly Shaanxi Weinan Huaren] [UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On October 11, 2011, Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) (“Biostar” or the “Company”), through its wholly owned variable interest entity, Shaanxi Aoxing Pharmaceutical Co., Ltd., acquired 100% equity interest (the “Acquisition”) of Shaanxi Weinan Aoxing Pharmaceutical, LLC (formerly Shaanxi Weinan Huaren Pharmaceutical, Ltd.) (“Shaanxi Weinan”) at a cash purchase consideration of RMB61]
[FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): December 20, 2011 NF ENERGY SAVING CORPORATION Delaware 000-50155 02-0563302 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) Room 3105, Block C, 390 Qingnian Avenue Heping District Shenyang, P.R. China 11000221 (Zip Code) (8624) 2560-9750 (Former Name or Former Address, if Changed Since Last Report) see]
[FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): December 20, 2011 NF ENERGY SAVING CORPORATION Delaware 000-50155 02-0563302 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) Room 3105, Block C, 390 Qingnian Avenue Heping District Shenyang, P.R. China 11000221 (Zip Code) (8624) 2560-9750 (Former Name or Former Address, if Changed Since Last Report) see]
[IMPORTANT NOTICE - INDEPENDENTENT AND BROKERMPENSATION NOVERAGE IS PROVIDED BY THIS NOTICE. THIS NOTICE DOES NOT AMEND ANY PROVISION OF YOUR POLICY. YOU SHOULD REVIEW YOUR ENTIRE POLICYREFULLY FORMPLETE INFORMATION ON THEVERAGES PROVIDED AND TO DETERMINE YOUR RIGHTS AND DUTIES UNDER YOUR POLICY. PLEASENTACT YOURENT OR BROKER IF YOU HAVE ANY QUESTIONSOUT THIS NOTICE OR]
